CRNX News & Events

ALX Oncology (ALXO) announced the appointment of Jeff Knight as chief development and operating officer, effective April 13. Most recently, he served as chief development and operating officer at Crinetics (CRNX).

Crinetics announced the submission of a marketing authorization application to Brazil's National Health Surveillance Agency, or ANVISA, for Palsonify, the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the proposed treatment of acromegaly in adults.